Atrium Therapeutics launched as a public company following Novartis’ acquisition of Avidity, carrying roughly $270 million in cash and two lead RNA‑delivery candidates targeting PRKAG2 syndrome and PLN cardiomyopathy. The spinout concentrates Avidity’s targeted RNA delivery platform and rare‑cardiac disease expertise into a focused organization. CEO Kathleen Gallagher said the capital will support IND‑enabling work and move the lead program ATR‑1072 toward clinical proof‑of‑concept. Atrium positions itself to address high‑unmet needs in genetically driven cardiomyopathies using precision RNA modalities derived from Avidity’s platform.